Literature DB >> 27222651

Standard and Targeted Biopsy During Follow-up for Active Surveillance.

Brian Weiss1, Stacy Loeb2.   

Abstract

Year:  2015        PMID： 27222651      PMCID： PMC4857906          DOI： 10.3909/riu0670a

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  7 in total

1.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

Authors:  Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

Review 2.  Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Authors:  Stacy Loeb; Sophie M Bruinsma; Joseph Nicholson; Alberto Briganti; Tom Pickles; Yoshiyuki Kakehi; Sigrid V Carlsson; Monique J Roobol
Journal:  Eur Urol       Date:  2014-10-31       Impact factor: 20.096

3.  Risk stratification of men choosing surveillance for low risk prostate cancer.

Authors:  Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter
Journal:  J Urol       Date:  2010-03-20       Impact factor: 7.450

4.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

5.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

6.  Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?

Authors:  Jim C Hu; Edward Chang; Shyam Natarajan; Daniel J Margolis; Malu Macairan; Patricia Lieu; Jiaoti Huang; Geoffrey Sonn; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

7.  Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.

Authors:  K Clint Cary; Janet E Cowan; Melissa Sanford; Katsuto Shinohara; Nannette Perez; June M Chan; Maxwell V Meng; Peter R Carroll
Journal:  Eur Urol       Date:  2013-09-09       Impact factor: 20.096
  7 in total
  1 in total

1.  Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer.

Authors:  A Finelli; M Komisarenko; L J Martin; N Timilshina; K Jain; J Morris; A Zlotta; G Kulkarni; N Perlis; T van der Kwast; A Evans; S Ghai; N Fleshner; S M H Alibhai; R J Hamilton
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-03-09       Impact factor: 5.554
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.